ABSI vs ALIT vs WTW vs RXRX vs MMC

For growth investors, Recursion Pharmaceuticals, Inc.

(RXRX) is the stronger pick with 26. 9% revenue growth year-over-year, versus -38. 2% for Absci Corporation (ABSI). Willis Towers Watson Public Limited Company (WTW) offers the better valuation at 15. 9x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Absci Corporation (ABSI) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Willis Towers Watson Public Limited Company (WTW) is the cheapest at 15.

9x versus Marsh & McLennan Companies, Inc. at 21. 3x. On forward P/E, Alight, Inc. is actually cheaper at 3. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Willis Towers Watson Public Limited Company wins at 0. 81x versus Marsh & McLennan Companies, Inc. 's 0. 88x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Marsh & McLennan Companies, Inc.

(MMC) delivered a total return of +36. 5%, compared to -89. 4% for Alight, Inc. (ALIT). Over 10 years, the gap is even starker: MMC returned +209. 8% versus ALIT's -89. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Willis Towers Watson Public Limited Company (WTW) is the lower-risk stock at 0.

13β versus Recursion Pharmaceuticals, Inc. 's 3. 18β — meaning RXRX is approximately 2262% more volatile than WTW relative to the S&P 500. On balance sheet safety, Absci Corporation (ABSI) carries a lower debt/equity ratio of 3% versus 192% for Alight, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Recursion Pharmaceuticals, Inc.

(RXRX) is pulling ahead at 26. 9% versus -38. 2% for Absci Corporation (ABSI). On earnings-per-share growth, the picture is similar: Willis Towers Watson Public Limited Company grew EPS 1794% year-over-year, compared to -1924. 1% for Alight, Inc.. Over a 3-year CAGR, RXRX leads at 23. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Marsh & McLennan Companies, Inc.

(MMC) is the more profitable company, earning 16. 6% net margin versus -41. 1% for Absci Corporation — meaning it keeps 16. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MMC leads at 23. 8% versus -44. 5% for ABSI. At the gross margin level — before operating expenses — MMC leads at 42. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Willis Towers Watson Public Limited Company (WTW) is the more undervalued stock at a PEG of 0. 81x versus Marsh & McLennan Companies, Inc. 's 0. 88x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Alight, Inc. (ALIT) trades at 3. 0x forward P/E versus 16. 9x for Marsh & McLennan Companies, Inc. — 13. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALIT: 331. 9% to $3. 75.

In this comparison, ALIT (18.

8% yield), MMC (1. 8% yield), WTW (1. 4% yield) pay a dividend. ABSI, RXRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Marsh & McLennan Companies, Inc.

(MMC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 14), 1. 8% yield, +209. 8% 10Y return). Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 3. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MMC: +209. 8%, RXRX: -81. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ABSI (Healthcare) and ALIT (Technology) and WTW (Financial Services) and RXRX (Healthcare) and MMC (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ABSI is a small-cap quality compounder stock; ALIT is a small-cap income-oriented stock; WTW is a mid-cap deep-value stock; RXRX is a small-cap high-growth stock; MMC is a mid-cap quality compounder stock. ALIT, WTW, MMC pay a dividend while ABSI, RXRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.